DE69836422D1 - N-heterocyclische derivate als nos inhibitoren - Google Patents
N-heterocyclische derivate als nos inhibitorenInfo
- Publication number
- DE69836422D1 DE69836422D1 DE69836422T DE69836422T DE69836422D1 DE 69836422 D1 DE69836422 D1 DE 69836422D1 DE 69836422 T DE69836422 T DE 69836422T DE 69836422 T DE69836422 T DE 69836422T DE 69836422 D1 DE69836422 D1 DE 69836422D1
- Authority
- DE
- Germany
- Prior art keywords
- heterocyclic derivatives
- nos inhibitors
- inhibitors
- compounds
- nitric oxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80897597A | 1997-02-19 | 1997-02-19 | |
US808975 | 1997-02-19 | ||
US2512498A | 1998-02-17 | 1998-02-17 | |
US25124 | 1998-02-17 | ||
PCT/US1998/003176 WO1998037079A1 (en) | 1997-02-19 | 1998-02-19 | N-heterocyclic derivatives as nos inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69836422D1 true DE69836422D1 (de) | 2006-12-28 |
DE69836422T2 DE69836422T2 (de) | 2007-06-14 |
Family
ID=26699322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69836422T Expired - Lifetime DE69836422T2 (de) | 1997-02-19 | 1998-02-19 | N-heterocyclische derivate als nos inhibitoren |
Country Status (21)
Country | Link |
---|---|
EP (2) | EP1754703A3 (de) |
JP (1) | JP4495257B2 (de) |
KR (1) | KR20000075615A (de) |
CN (1) | CN1100777C (de) |
AT (1) | ATE345339T1 (de) |
AU (1) | AU732969B2 (de) |
CA (1) | CA2281545C (de) |
CZ (1) | CZ2008628A3 (de) |
DE (1) | DE69836422T2 (de) |
DK (1) | DK0968206T3 (de) |
ES (1) | ES2277382T3 (de) |
GB (1) | GB2338957B (de) |
HK (1) | HK1025952A1 (de) |
IL (1) | IL131475A0 (de) |
NO (1) | NO321664B1 (de) |
NZ (1) | NZ337861A (de) |
PL (1) | PL335235A1 (de) |
PT (1) | PT968206E (de) |
RU (1) | RU2241708C2 (de) |
SK (1) | SK286779B6 (de) |
WO (1) | WO1998037079A1 (de) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6432947B1 (en) * | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
EP0970072A1 (de) * | 1997-03-11 | 2000-01-12 | E.I. Dupont De Nemours And Company | Herbizide heteroaryl-azole |
DE19836697A1 (de) * | 1998-08-13 | 2000-02-17 | Hoechst Marion Roussel De Gmbh | Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US6432959B1 (en) * | 1998-12-23 | 2002-08-13 | Schering Corporation | Inhibitors of farnesyl-protein transferase |
IL142816A0 (en) | 1998-12-24 | 2002-03-10 | Du Pont Pharm Co | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
AUPQ142599A0 (en) * | 1999-07-05 | 1999-07-29 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
US7037916B2 (en) | 1999-07-15 | 2006-05-02 | Pharmacopeia Drug Discovery, Inc. | Pyrimidine derivatives as IL-8 receptor antagonists |
ATE250053T1 (de) | 1999-07-15 | 2003-10-15 | Pharmacopeia Inc | Bradikinin b1 rezeptor antagonisten |
US6503902B2 (en) | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
US6960576B2 (en) | 1999-09-13 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production |
EP1222176A1 (de) | 1999-10-08 | 2002-07-17 | Bristol-Myers Squibb Pharma Company | Amino-laktam-sulfonamide als inhibitoren der bildung von a-beta-protein |
US6462046B2 (en) * | 2000-01-06 | 2002-10-08 | Advanced Syntech, Llc | Heterocycle derivatives as PPAR-gamma agonists |
DE10005570A1 (de) | 2000-02-09 | 2001-08-16 | Bayer Ag | Verfahren zur Herstellung von 2-Methoxyethoxy-benzolen und neue 2-Methoxyethoxy-benzylcyanide |
US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
GB2361473C (en) * | 2000-03-08 | 2005-06-28 | Microgenics Corp | Ecstasy-class analogs and use of same in detection of ecstasy-class compounds |
US6525051B2 (en) * | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
US6495540B2 (en) | 2000-03-28 | 2002-12-17 | Bristol - Myers Squibb Pharma Company | Lactams as inhibitors of A-β protein production |
BR0110051A (pt) | 2000-04-03 | 2004-12-07 | Bristol Myers Squibb Pharma Co | Composto, uso do composto, composição farmacêutica e método de tratamento do mal de alzheimer |
CN1436175A (zh) | 2000-04-03 | 2003-08-13 | 布里斯托尔-迈尔斯斯奎布药品公司 | 作为Aβ-蛋白生产抑制剂的环状内酰胺 |
EP1289966A1 (de) | 2000-04-11 | 2003-03-12 | Bristol-Myers Squibb Pharma Company | Lactamderivate als inhibitoren von a beta protein-produktion |
WO2001092235A1 (en) | 2000-06-01 | 2001-12-06 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
ATE399766T1 (de) * | 2000-10-20 | 2008-07-15 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische heterozyklen |
US20030055249A1 (en) * | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
JPWO2003026661A1 (ja) * | 2001-09-14 | 2005-01-06 | 山之内製薬株式会社 | インスリン分泌促進剤及び新規なピリミジン誘導体 |
WO2003027068A2 (en) * | 2001-09-24 | 2003-04-03 | Elan Pharmaceuticals, Inc. | Substituted amines for the treatment of neurological disorders |
US6982259B2 (en) * | 2002-04-30 | 2006-01-03 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
EP1795192A3 (de) * | 2002-04-30 | 2008-05-07 | Bayer Schering Pharma Aktiengesellschaft | 1-(pyridazin-3-yl)-Imidazol Derivaten als NO-Synthase (NOS) Hemmer |
MXPA05001255A (es) * | 2002-08-02 | 2005-06-08 | Pharmacia Corp | Metodos para el tratamiento y prevencion de condiciones gastrointestinales. |
WO2004019986A1 (en) * | 2002-08-29 | 2004-03-11 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
WO2004052862A1 (ja) | 2002-12-10 | 2004-06-24 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
OA13309A (en) | 2002-12-20 | 2007-04-13 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth. |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2004069829A1 (en) * | 2003-01-10 | 2004-08-19 | Pharmacopeia Drug Discovery, Inc. | (2s)-2-((pyrimidin-4-yl)amino)-4-methylpentanoic acid aminoethylamid derivatives as il-8 receptor modulators for the treatment of atherosclerosis and rheumatoid arthritis |
JP2006519806A (ja) * | 2003-03-07 | 2006-08-31 | グラクソ グループ リミテッド | 尿素誘導体および疼痛治療におけるバニロイド受容体拮抗剤としてのそれらの使用。 |
US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
GEP20084572B (en) | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
KR20120091276A (ko) | 2004-02-20 | 2012-08-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 바이러스 폴리머라제 억제제 |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
EP1758887A1 (de) | 2004-05-14 | 2007-03-07 | Pfizer Products Incorporated | Pyrimidinderivate zur behandlung von anormalem zellwachstum |
WO2005111022A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
JP2007537235A (ja) | 2004-05-14 | 2007-12-20 | ファイザー・プロダクツ・インク | 異常細胞増殖の治療用ピリミジン誘導体 |
KR20070053205A (ko) | 2004-09-17 | 2007-05-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 의약 조성물 |
MX2007003154A (es) * | 2004-09-17 | 2007-05-15 | Vertex Pharma | Compuestos de diaminotriazol de utilidad como inhibidores de proteina quinasa. |
EP1827434B1 (de) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Chinolin- und chinazolinanaloge und deren verwendung als medikamente zur krebsbehandlung |
JP2008521908A (ja) * | 2004-12-01 | 2008-06-26 | カリプシス・インコーポレーテッド | 誘導型一酸化窒素シンターゼ阻害剤 |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
WO2006113097A2 (en) * | 2005-04-15 | 2006-10-26 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
EP1925676A4 (de) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | Testverfahren für die wirkung eines vaskularisierungsinhibitors |
WO2007020888A1 (ja) | 2005-08-12 | 2007-02-22 | Takeda Pharmaceutical Company Limited | 脳・神経細胞保護剤および睡眠障害治療薬 |
WO2007039581A1 (en) * | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted diazabenzophenone compounds |
BRPI0620526A2 (pt) * | 2005-11-28 | 2011-11-16 | Kalypsys Inc | sal de acetato e método para alcançar um efeito em um paciente |
US8017612B2 (en) * | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
EP2036557B1 (de) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumorales mittel gegen schilddrüsenkrebs |
WO2008006583A1 (en) * | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
WO2008026748A1 (fr) | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
WO2008042925A1 (en) * | 2006-10-04 | 2008-04-10 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
EP1939181A1 (de) * | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression |
US8962655B2 (en) | 2007-01-29 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated gastric cancer |
AU2008325608B2 (en) | 2007-11-09 | 2013-03-14 | Eisai R & D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
MX2011001349A (es) * | 2008-08-04 | 2011-08-17 | Chidi Inc | Ciertos inhibidores de quinurenin-3-monooxigenasa, composiciones farmaceuticas y metodos para su uso. |
EP3470402B1 (de) | 2009-11-12 | 2021-01-06 | Pharmatrophix Inc. | Kristalline formen aus neurotrophinmimetischen verbindungen und deren salzen |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
ES2573515T3 (es) | 2010-06-25 | 2016-06-08 | Eisai R&D Management Co., Ltd. | Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados |
RU2580609C2 (ru) | 2011-04-18 | 2016-04-10 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое терапевтическое средство |
ES2705950T3 (es) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib |
PT2750677T (pt) | 2011-08-30 | 2017-07-03 | Chdi Foundation Inc | Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos |
EP2763672B1 (de) * | 2011-10-06 | 2016-08-10 | Merck Sharp & Dohme Corp. | 1,3-substituierte azetidin-pde10-inhibitoren |
WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
HUE054031T2 (hu) | 2012-04-24 | 2021-08-30 | Vertex Pharma | DNS-PK inhibitorok |
EP2937337A4 (de) | 2012-12-21 | 2016-06-22 | Eisai R&D Man Co Ltd | Amorphe form von chinolinderivaten und verfahren zur herstellung davon |
HUE041544T2 (hu) | 2013-03-12 | 2019-05-28 | Vertex Pharma | DNS-PK inhibitorok |
NZ714049A (en) | 2013-05-14 | 2020-05-29 | Eisai R&D Man Co Ltd | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
SI3057953T1 (sl) | 2013-10-17 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Ko-kristali(s)-n-metil-8-(1-((2'-metil-(4,5'-bipimiridin)-6-il)amino) propan-2-il)kinolin-4-karboksamida in njegovi devterirani derivati kot inhibitorji dna-pk |
UA120856C2 (uk) | 2014-07-17 | 2020-02-25 | Кхді Фаундейшн, Інк. | Способи та композиції для лікування розладів, пов'язаних з віл |
TWI721954B (zh) | 2014-08-28 | 2021-03-21 | 日商衛材R&D企管股份有限公司 | 高純度喹啉衍生物及其生產方法 |
RU2017128583A (ru) | 2015-02-25 | 2019-03-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Способ ослабления горечи хинолинового производного |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
AU2016279474B2 (en) | 2015-06-16 | 2021-09-09 | Eisai R&D Management Co., Ltd. | Anticancer agent |
WO2017214286A1 (en) * | 2016-06-07 | 2017-12-14 | Northwestern University | Substituted 4-(1-pyrrolidinyl)pyrimidine compounds as dimerization inhibitors of neuronal nitric oxide synthase |
CA3038657A1 (en) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors |
RU2732297C2 (ru) * | 2018-11-14 | 2020-09-15 | Общество с ограниченной ответственностью "Гурус БиоФарм" | Производные нестероидных противовоспалительных средств |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6339875A (ja) * | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
DK0640599T3 (da) * | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-Aminopyrimidin-derivater |
-
1998
- 1998-02-19 AT AT98906555T patent/ATE345339T1/de not_active IP Right Cessation
- 1998-02-19 KR KR1019997007678A patent/KR20000075615A/ko not_active Application Discontinuation
- 1998-02-19 WO PCT/US1998/003176 patent/WO1998037079A1/en active Application Filing
- 1998-02-19 NZ NZ337861A patent/NZ337861A/xx unknown
- 1998-02-19 DE DE69836422T patent/DE69836422T2/de not_active Expired - Lifetime
- 1998-02-19 CA CA002281545A patent/CA2281545C/en not_active Expired - Fee Related
- 1998-02-19 CZ CZ2008-628A patent/CZ2008628A3/cs unknown
- 1998-02-19 RU RU99120077/04A patent/RU2241708C2/ru active
- 1998-02-19 DK DK98906555T patent/DK0968206T3/da active
- 1998-02-19 CN CN98804281A patent/CN1100777C/zh not_active Expired - Fee Related
- 1998-02-19 GB GB9919686A patent/GB2338957B/en not_active Expired - Fee Related
- 1998-02-19 IL IL13147598A patent/IL131475A0/xx not_active IP Right Cessation
- 1998-02-19 PL PL98335235A patent/PL335235A1/xx not_active Application Discontinuation
- 1998-02-19 ES ES98906555T patent/ES2277382T3/es not_active Expired - Lifetime
- 1998-02-19 AU AU61749/98A patent/AU732969B2/en not_active Ceased
- 1998-02-19 EP EP06023449A patent/EP1754703A3/de not_active Withdrawn
- 1998-02-19 JP JP53685398A patent/JP4495257B2/ja not_active Expired - Fee Related
- 1998-02-19 EP EP98906555A patent/EP0968206B8/de not_active Expired - Lifetime
- 1998-02-19 SK SK1135-99A patent/SK286779B6/sk not_active IP Right Cessation
- 1998-02-19 PT PT98906555T patent/PT968206E/pt unknown
-
1999
- 1999-08-19 NO NO19993996A patent/NO321664B1/no not_active IP Right Cessation
-
2000
- 2000-07-11 HK HK00104236A patent/HK1025952A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69836422D1 (de) | N-heterocyclische derivate als nos inhibitoren | |
ATE256681T1 (de) | N-heterozyklische derivate als nos inhibitoren | |
DE60101000D1 (de) | N-heterocyclische derivate als nos inhibitoren | |
DE69416848T2 (de) | Amidino-derivate als no-synthetase inhibitoren | |
ATE353216T1 (de) | 1-substituierten imidazol derivaten als nos inhibitoren | |
ATE498600T1 (de) | Inden derivate als pharmazeutika | |
SE9904128D0 (sv) | Novel compounds | |
DE60222465D1 (de) | Pyrazolopyridin-derivate als antiherpesmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: BERLEX, INC., RICHMOND, CALIF., US Owner name: PHARMACOPEIA, INC., PRINCETON, N.J., US |
|
8364 | No opposition during term of opposition | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: DF-MP, 80333 MUENCHEN |